TABLE 1.
Expression of low and high-affinity Fcγ receptors and CAR and effects of CARex-Fc on Ad-mediated transduction
| Cell line | Expression of:
|
Transduction with or without CARex-Fc | ||||
|---|---|---|---|---|---|---|
| CD16 (FcγRIII) | CD32 (FcγRII) | CD64 (FcγRI) | CAR (FACS) | CAR (Western) | ||
| Primary NK cells | ++ | − | − | − | − | No change |
| Jurkat (acute T-cell leukemia) | − | − | − | ±a | ±a | 40% inhibition at highest CARex-Fc |
| Daudi (Burkitt's B lymphoma) | − | − | − | − | − | No change |
| Raji (Burkitt's B lymphoma) | − | ++ | − | + | + | No change |
| Ramos (Burkitt's B lymphoma) | − | − | − | − | + | No change |
| K562 (chronic myelogenous leukemia) | − | ++ | − | − | + | 20% inhibition at highest CARex-Fc |
| U937 (H) (monocytic lymphoma) | − | − | − | − | − | 20% inhibition at highest CARex-Fc |
| U937 (D) (monocytic lymphoma, alternative subline) | − | ++ | + | − | − | Up to 250-fold increase |
| HL-60 (promyelocytic leukemia) | − | + | ± | − | − | 5-fold- increase |
| SigM5 (AML) | − | + | ± | − | − | 2–3-fold increase |
| Kasumi-1 (AML) | − | + | ± | − | − | 2–3-fold increase |
| THP-1 (acute monocytic leukemia) | − | ++ | ++ | − | − | Up to 250-fold increase |
| Primary AML cells | − | + | ++ | − | − | Up to 200-fold increase |
a
Weak signal.